Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04827862 · ClinicalTrials.gov registry record · Phase 2

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

A Phase 2 study of Non-Hodgkin Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.

Active
Registry status
Phase 2
Development phase
6
Enrollment target
1
Study location

NCT04827862: Active Phase 2 study of Non-Hodgkin Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.

NCT04827862 is a Phase 2 study of Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6 participants, below the 168-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04827862, a Phase 2 study of Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This study is an open-label Phase II trial of non-Hodgkin lymphoma patients receiving initial treatment with the immunomodulatory agent, pembrolizumab, plus low-dose (4 Gy x 5) involved-site radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease (≥1.0 cm), and must be eligible for treatment with pembrolizumab. Biosamples (blood and, where available, tumor) will be collected as outlined below. Pembrolizumab will be continued after RT until disease progression, drug intolerance, or at the discretion of the treating medical oncologist.

Conditions Studied

Non-Hodgkin Lymphoma

Interventions

  • DRUG Pembrolizumab

Study Locations (1)

Pennsylvania

  • Abamson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2022-07-01
Est. Completion 2026-11
Phase Phase 2
Abramson Cancer Center at Penn Medicine

402 total trials

What the registry record for NCT04827862 still lists

NCT04827862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 168-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.

NCT04827862 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04827862 about?

NCT04827862 is a clinical study titled "RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy". This study is an open-label Phase II trial of non-Hodgkin lymphoma patients receiving initial treatment with the immunomodulatory agent, pembrolizumab, plus low-dose (4 Gy x 5) involved-site radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease (≥1.0 cm), ...

What is the current status of trial NCT04827862?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2022-07-01. Estimated completion is 2026-11.

What conditions does trial NCT04827862 study?

This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT04827862?

The interventions under investigation include: Pembrolizumab (DRUG).

Who is sponsoring clinical trial NCT04827862?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04827862 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04827862's enrollment target sits among peer trials

6 106th of 106 the lowest of 106 other Non-Hodgkin Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04827862, the US trial registry maintained by the National Library of Medicine. NCT04827862 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.